Theravance Biopharma, Inc. (TBPH)
17.03
0.00 (0.00%)
USD |
NASDAQ |
Oct 02, 16:00
Theravance Biopharma Net Income (Quarterly) : -5.898M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -5.898M |
| March 31, 2026 | -4.933M |
| December 31, 2025 | 61.02M |
| September 30, 2025 | 3.615M |
| June 30, 2025 | 54.84M |
| March 31, 2025 | -13.58M |
| December 31, 2024 | -15.53M |
| September 30, 2024 | -12.70M |
| June 30, 2024 | -16.53M |
| March 31, 2024 | -11.66M |
| December 31, 2023 | -8.511M |
| September 30, 2023 | -8.95M |
| June 30, 2023 | -15.64M |
| March 31, 2023 | -22.09M |
| December 31, 2022 | -14.26M |
| September 30, 2022 | -16.02M |
| June 30, 2022 | -22.79M |
| March 31, 2022 | -40.26M |
| December 31, 2021 | -57.82M |
| September 30, 2021 | -55.91M |
| June 30, 2021 | -52.40M |
| March 31, 2021 | -79.68M |
| December 31, 2020 | -58.43M |
| September 30, 2020 | -73.64M |
| June 30, 2020 | -62.89M |
| Date | Value |
|---|---|
| March 31, 2020 | -83.05M |
| December 31, 2019 | -65.61M |
| September 30, 2019 | -58.43M |
| June 30, 2019 | -39.84M |
| March 31, 2019 | -72.58M |
| December 31, 2018 | -50.19M |
| September 30, 2018 | -59.43M |
| June 30, 2018 | -40.82M |
| March 31, 2018 | -65.09M |
| December 31, 2017 | -86.92M |
| September 30, 2017 | -66.88M |
| June 30, 2017 | -66.29M |
| March 31, 2017 | -65.32M |
| December 31, 2016 | -67.33M |
| September 30, 2016 | -33.96M |
| June 30, 2016 | -47.22M |
| March 31, 2016 | -42.15M |
| December 31, 2015 | -44.83M |
| September 30, 2015 | -47.31M |
| June 30, 2015 | -47.60M |
| March 31, 2015 | -42.47M |
| December 31, 2014 | -64.31M |
| September 30, 2014 | -54.50M |
| June 30, 2014 | -58.22M |
| March 31, 2014 | -60.02M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Viatris, Inc. | -118.80M |
| Ocular Therapeutix, Inc. | -78.76M |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 20.73M |
| Total Expenses (Quarterly) | 26.63M |
| EPS Diluted (Quarterly) | -0.1142 |
| Enterprise Value | 567.41M |
| Gross Profit Margin (Quarterly) | 93.04% |
| Profit Margin (Quarterly) | -28.45% |
| Earnings Yield | 5.93% |
| Operating Earnings Yield | 0.25% |
| Normalized Earnings Yield | 7.024 |